ATNM
Price
$1.43
Change
+$0.03 (+2.14%)
Updated
Dec 9 closing price
Capitalization
44.61M
93 days until earnings call
Intraday BUY SELL Signals
GMAB
Price
$30.93
Change
-$1.01 (-3.16%)
Updated
Dec 9 closing price
Capitalization
19.74B
57 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATNM vs GMAB

Header iconATNM vs GMAB Comparison
Open Charts ATNM vs GMABBanner chart's image
Actinium Pharmaceuticals
Price$1.43
Change+$0.03 (+2.14%)
Volume$259.54K
Capitalization44.61M
Genmab A/S ADS
Price$30.93
Change-$1.01 (-3.16%)
Volume$1.05M
Capitalization19.74B
ATNM vs GMAB Comparison Chart in %
ATNM
Daily Signal:
Gain/Loss:
GMAB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATNM vs. GMAB commentary
Dec 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATNM is a Buy and GMAB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 10, 2025
Stock price -- (ATNM: $1.43 vs. GMAB: $30.93)
Brand notoriety: ATNM and GMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATNM: 96% vs. GMAB: 51%
Market capitalization -- ATNM: $44.61M vs. GMAB: $19.74B
ATNM [@Biotechnology] is valued at $44.61M. GMAB’s [@Biotechnology] market capitalization is $19.74B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.88B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATNM’s FA Score shows that 0 FA rating(s) are green whileGMAB’s FA Score has 0 green FA rating(s).

  • ATNM’s FA Score: 0 green, 5 red.
  • GMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, GMAB is a better buy in the long-term than ATNM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATNM’s TA Score shows that 4 TA indicator(s) are bullish while GMAB’s TA Score has 6 bullish TA indicator(s).

  • ATNM’s TA Score: 4 bullish, 3 bearish.
  • GMAB’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, GMAB is a better buy in the short-term than ATNM.

Price Growth

ATNM (@Biotechnology) experienced а +3.62% price change this week, while GMAB (@Biotechnology) price change was -2.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.72%. For the same industry, the average monthly price growth was +8.72%, and the average quarterly price growth was +58.80%.

Reported Earning Dates

ATNM is expected to report earnings on Mar 13, 2026.

GMAB is expected to report earnings on Feb 05, 2026.

Industries' Descriptions

@Biotechnology (+6.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($19.7B) has a higher market cap than ATNM($44.6M). GMAB YTD gains are higher at: 48.203 vs. ATNM (13.492). GMAB has higher annual earnings (EBITDA): 1.71B vs. ATNM (-36.52M). GMAB has more cash in the bank: 3.41B vs. ATNM (53.4M). ATNM has less debt than GMAB: ATNM (1.14M) vs GMAB (142M). GMAB has higher revenues than ATNM: GMAB (3.47B) vs ATNM (90K).
ATNMGMABATNM / GMAB
Capitalization44.6M19.7B0%
EBITDA-36.52M1.71B-2%
Gain YTD13.49248.20328%
P/E RatioN/A13.54-
Revenue90K3.47B0%
Total Cash53.4M3.41B2%
Total Debt1.14M142M1%
FUNDAMENTALS RATINGS
ATNM vs GMAB: Fundamental Ratings
ATNM
GMAB
OUTLOOK RATING
1..100
1919
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
63
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9935
PRICE GROWTH RATING
1..100
5840
P/E GROWTH RATING
1..100
10084
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATNM's Valuation (63) in the Biotechnology industry is in the same range as GMAB (63) in the null industry. This means that ATNM’s stock grew similarly to GMAB’s over the last 12 months.

ATNM's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GMAB (100) in the null industry. This means that ATNM’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's SMR Rating (35) in the null industry is somewhat better than the same rating for ATNM (99) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than ATNM’s over the last 12 months.

GMAB's Price Growth Rating (40) in the null industry is in the same range as ATNM (58) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ATNM’s over the last 12 months.

GMAB's P/E Growth Rating (84) in the null industry is in the same range as ATNM (100) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ATNM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATNMGMAB
RSI
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 1 day ago
56%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
68%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
58%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
64%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
68%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
62%
Advances
ODDS (%)
Bullish Trend 8 days ago
70%
Bullish Trend 13 days ago
65%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
69%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
ATNM
Daily Signal:
Gain/Loss:
GMAB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PNRG192.167.16
+3.87%
PrimeEnergy Resources Corp
LTRN3.880.03
+0.78%
Lantern Pharma
TRYIF6.57N/A
N/A
Toray Industries Inc.
CBSH52.08-0.13
-0.25%
Commerce Bancshares Inc.
ADNT18.70-0.05
-0.27%
Adient plc

ATNM and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATNM has been loosely correlated with RXRX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ATNM jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATNM
1D Price
Change %
ATNM100%
+2.14%
RXRX - ATNM
41%
Loosely correlated
-1.04%
CRBU - ATNM
41%
Loosely correlated
-1.06%
CRSP - ATNM
41%
Loosely correlated
-0.56%
HOWL - ATNM
40%
Loosely correlated
+1.00%
IPSC - ATNM
39%
Loosely correlated
+3.81%
More

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-3.16%
GNMSF - GMAB
58%
Loosely correlated
N/A
AXON - GMAB
47%
Loosely correlated
-1.17%
TECH - GMAB
40%
Loosely correlated
-2.44%
ARGX - GMAB
38%
Loosely correlated
-1.26%
BMRN - GMAB
37%
Loosely correlated
+0.83%
More